Zactima for Recurrent or Progressive Brain Tumors
Name of the Trial
Why This Trial Is Important
A new drug called Zactima (ZD6474) targets both blood vessel growth and tumor cells themselves. "It binds to two key molecular targets, one on the tumor (EGFR) and one on blood vessels (VEGFR)," explained Dr. Fine. This disrupts cell-signaling pathways that the cancer cells need to grow and survive. Other drugs for malignant glioma may bind to one or the other of these targets, said Dr. Fine, but "we hope hitting them both together will increase [antitumor] activity."
Many patients with malignant glioma take a type of drug called an enzyme-inducing anti-epileptic drug (EIAED) to help control cancer-induced seizures. Patients taking EIAEDs need higher doses of Zactima because EIAEDs cause Zactima to be processed faster by the body. The phase I part of this trial will determine the dose of Zactima required for patients taking EIAEDs. The phase II part will enroll patients not taking EIAEDs, and will look at Zactima's antitumor activity.
Preliminary results of the trial have been promising, said Dr. Fine. "We've already seen signs of significant biologic activity and some tumor shrinkage. Though not in every patient, we're definitely seeing some very profound effects."
Who Can Join This Trial
Study Sites and Contact Information
An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.